RT Journal Article
SR Electronic
T1 Trial of Optimal Personalised Care After Treatment—Gynaecological Cancer (TOPCAT-G): A Randomized Feasibility Trial
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 401
OP 411
DO 10.1097/IGC.0000000000001179
VO 28
IS 2
A1 Morrison, Val
A1 Spencer, Llinos H.
A1 Totton, Nikki
A1 Pye, Kirstie
A1 Yeo, Seow Tien
A1 Butterworth, Caryl
A1 Hall, Liz
A1 Whitaker, Rhiannon
A1 Edwards, Rhiannon Tudor
A1 Timmis, Laura J.
A1 Hoare, Zoe
A1 Neal, Richard D.
A1 Wilkinson, Clare
A1 Leeson, Simon
YR 2018
UL http://ijgc.bmj.com/content/28/2/401.abstract
AB Objective This study aimed to evaluate the feasibility of completing a parallel-group randomized controlled trial to compare usual follow-up care for women who have completed treatment of gynecological cancer against a nurse-led telephone intervention, known as Optimal Personalised Care After Treatment—Gynaecological.Methods The unblinded trial aimed to recruit patients who had completed treatment of cervical, endometrial, epithelial ovarian, or vulval cancer within the previous 3 months at 3 North Wales hospitals. We randomized participants to either usual hospital-based follow-up or specialist nurse–led telephone education, empowerment, and structured needs assessment follow-up. The primary outcomes assessed the feasibility of running a larger trial including patient eligibility, recruitment and retention rates, and outcome measure completion. Secondary outcomes were generic and health-related quality of life and a patient self-report health service use (Client Service Receipt Inventory) data collected at 3 time points (baseline, 3 months, and 6 months).Results Of the 58 women screened, 44 were eligible (76%) and 24 (55%) were recruited and randomized (12:12 to control and intervention, respectively). One participant was lost to follow-up. Recruited participants had a mean (SD) age of 60 (11.2) years and were approximately 5 months from their initial diagnosis (mean [SD], 159 [58] days). Seventeen (71%) of the participants had an endometrial cancer diagnosis. All outcome measure completion rates exceeded 96%. Although not a core feasibility objective, analyses of outcome measures indicated positive changes in quality of life and well-being within the Optimal Personalised Care After Treatment—Gynaecological group; exploratory cost consequence analysis indicated that the nurse-led intervention had a mean total service use cost of £27 per patient (bootstrapped 95% confidence interval, −£290 to £240) lower than did the standard care group.Conclusion Eligibility, recruitment, and retention rates as well as outcome measure completion showed that the trial is feasible.